Document Detail

Olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide triple combination for hypertension.
MedLine Citation:
PMID:  21166525     Owner:  NLM     Status:  MEDLINE    
Hypertension is an increasingly prevalent cardiovascular risk factor associated with high rates of morbidity and mortality. Lowering blood pressure (BP) to recommended levels reduces the risk of hypertension-associated cardiovascular events. Despite current treatment options and recommendations, the BP of many patients remains suboptimally controlled. There is a need for more effective management in patients not achieving BP goals on current monotherapy or combination therapy. Regimens combining three or more antihypertensive agents have been shown to increase the proportion of patients achieving BP goals. Recent data suggest that the combination of olmesartan medoxomil, amlodipine and hydrochlorothiazide is a rational treatment option offering safe and effective BP reductions and goal attainment in a greater proportion of patients compared with dual-combination regimens. As the understanding of the importance of BP control grows, treatment options that enable patients to achieve BP goals quickly and safely will become increasingly important in hypertension management.
C Venkata S Ram
Related Documents :
23489065 - The contribution of the c-824t tyrosine hydroxylase polymorphism to the prevalence of h...
22710205 - Experimental intra-abdominal hypertension attenuates the benefit of positive end-expira...
15088995 - Measuring the pressure pattern of the joint surface in the uninjured knee.
22188915 - Changes of the sphincter of oddi motility in dog after cholecystectomy.
8690845 - Autonomic mediation of short-term cardiovascular oscillations after acute hemorrhage in...
8450515 - Low blood pressure levels and signs of myocardial ischaemia: importance of left ventric...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert review of cardiovascular therapy     Volume:  9     ISSN:  1744-8344     ISO Abbreviation:  Expert Rev Cardiovasc Ther     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2010-12-20     Completed Date:  2011-03-29     Revised Date:  2013-08-15    
Medline Journal Info:
Nlm Unique ID:  101182328     Medline TA:  Expert Rev Cardiovasc Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  9-19     Citation Subset:  IM    
Texas Blood Pressure Institute, Dallas Nephrology Associates, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amlodipine / adverse effects,  pharmacology,  therapeutic use*
Antihypertensive Agents / adverse effects,  pharmacology,  therapeutic use*
Drug Combinations
Drug Therapy, Combination / adverse effects
Hydrochlorothiazide / adverse effects,  pharmacology,  therapeutic use*
Hypertension / drug therapy*
Imidazoles / adverse effects,  pharmacology,  therapeutic use*
Tetrazoles / adverse effects,  pharmacology,  therapeutic use*
Reg. No./Substance:
0/Antihypertensive Agents; 0/Drug Combinations; 0/Imidazoles; 0/Tetrazoles; 0/Tribenzor; 58-93-5/Hydrochlorothiazide; 6M97XTV3HD/olmesartan medoxomil; 88150-42-9/Amlodipine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Milestones of Directed Differentiation of Mouse and Human Embryonic Stem Cells into Telencephalic Ne...
Next Document:  Advances in cardiovascular research. 15th Annual Meeting of the European Council for Cardiovascular ...